<DOC>
	<DOCNO>NCT01041781</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine hydrochloride carboplatin , work different way stop growth tumor cell , either kill cell stop dividing . Pemetrexed disodium celecoxib may stop growth tumor cell block enzymes need cell growth . It yet know whether give gemcitabine hydrochloride pemetrexed disodium together carboplatin effective without celecoxib treat non-small cell lung cancer . PURPOSE : This randomized phase III trial study gemcitabine hydrochloride , pemetrexed disodium , carboplatin compare well work give together celecoxib placebo treat patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Gemcitabine Hydrochloride Pemetrexed Disodium Carboplatin With Without Celecoxib Treating Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To confirm beneficial effect gemcitabine hydrochloride pemetrexed disodium combination carboplatin without celecoxib patient advance non-small cell lung cancer express COX-2 . Secondary - To describe response rate patient treat regimen . - To describe distribution progression-free survival ( PFS ) overall survival patient treat regimen . - To compare PFS patient COX-2 index ≥ 2 ( adjust CYP2C9 genotype celecoxib trough concentration covariates ) treat regimen . - To correlate urinary PGE-M level COX-2 expression , COX-2 inhibition , outcome . - To evaluate association -765G/C polymorphism PTGS2 COX-2 expression non-small cell lung cancer specimen . - To characterize trough plasma celecoxib concentration use measure patient adherence study treatment may use future study correlation genotype pharmacodynamic outcome . OUTLINE : This multicenter study . Patients stratify accord gender , disease stage ( IIIB v IV ) , histology ( squamous cell carcinoma v non-squamous cell carcinoma ) , smoke status ( never/former light smoker [ define ≤ 10 pack year AND quit ≥ 1 year ago ] v smoker ) , COX-2 expression status ( COX-2 index ≥ 4 v COX-2 index ≥ 2 &lt; 4 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride* IV day 1 8 OR pemetrexed disodium* IV day 1 . Patients also receive carboplatin IV day 1 oral celecoxib twice daily day 1-21 . - Arm II : Patients receive gemcitabine hydrochloride* OR pemetrexed disodium* carboplatin arm I . Patients also receive oral placebo twice daily day 1-21 . - NOTE : *Patients squamous cell carcinoma receive gemcitabine hydrochloride ; patient non-squamous cell carcinoma receive pemetrexed disodium . In arm , treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . After completion 6 course , patient respond stable disease may continue receive celecoxib placebo alone absence disease progression unacceptable toxicity . Patients may undergo blood urine sample collection periodically correlative laboratory study . After completion study therapy , patient follow every 2 month 2 year every 6 month 3 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell carcinoma lung , include follow cell type : Adenocarcinoma Large cell carcinoma Squamous cell carcinoma Mixture type A tissue block must available time registration Tumor express COX2 ( COX2 index ≥ 2 ) Stage IIIB disease malignant pleural effusion , supraclavicular node involvement , contralateral hilar node involvement OR stage IV disease Patients stage IIIB disease eligible clinical trial involve combine chemotherapy chest irradiation eligible study Patients stage IV disease eligible Patients recurrent disease , amenable ( refuse ) potentially `` curative therapy , '' eligible Measurable nonmeasurable disease Measurable disease define lesion accurately measure ≥ 1 dimension ( long diameter record ) ≥ 2 cm conventional technique ≥ 1 cm spiral CT scan Nonmeasurable disease define lesion , include small lesion ( long diameter &lt; 20 mm conventional technique &lt; 10 mm spiral CT scan ) truly nonmeasurable lesion , include follow : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Abdominal mass confirm followed imaging technique Cystic lesion Patients symptomatic CNS metastasis eligible provide received prior therapy ( e.g. , surgery , radiotherapy , gamma knife ) , neurologically stable , steroid ≥ 14 day study entry Patients asymptomatic CNS metastasis without associate edema , shift , requirement steroid antiseizure medication may eligible discussion Study Chair Patients steroids least 7 day preregistration No leptomeningeal disease carcinomatous meningitis PATIENT CHARACTERISTICS : ECOG performance status 02 Granulocytes ≥ 1,500/μL Platelet count ≥ 100,000/μL Creatinine clearance ≥ 45 mL/min Bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.0 time upper limit normal ( ULN ) ( ≤ 5.0 time ULN liver metastasis present ) Serum albumin ≥ 2.5 mg/dL Not pregnant nursing Negative pregnancy test No `` currently active '' second malignancy nonmelanoma skin cancer Patients consider `` currently active '' malignancy complete therapy consider physician &lt; 30 % risk relapse No known hypersensitivity aspirin , NSAIDs , sulfonamides No active ulcer disease No history gastrointestinal bleeding within past three year None follow cardiovascular condition within past 6 month : Myocardial infarction Unstable angina Symptomatic congestive heart failure Serious uncontrolled cardiac arrhythmia Cerebrovascular accident transient ischemic attack Pulmonary embolism Symptomatic carotid artery peripheral vascular disease Deep vein thrombosis Other significant thromboembolic event PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy , immunotherapy , systemic therapy nonsmall cell lung cancer , include adjuvant therapy At least 2 week since prior surgery recover At least 7 day since prior radiotherapy At least 14 day since prior NSAIDs ( lowdose aspirin [ ≤ 325 mg daily ] ) , include follow : Celecoxib Choline Mg Trisalicylate ( Trilisate® ) Ibuprofen ( Advil® Motrin® ) Naproxen ( Aleve® , Naprosyn® Anaprox® ) Etodolac ( Lodine® ) Oxaprozin ( Daypro® ) Diflunisal ( Dolobid® ) Nabumetone ( Relafen® ) Tolmetin ( Tolectin® ) Valdecoxib ( Bextra® ) No chronic use NSAIDs ( i.e. , &gt; 4 week daily use ) Patients lowdose aspirin eligible No concurrent chemotherapy hormonal therapy ( megestrol acetate [ Megace ] appetite stimulation ) No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>